SAN DIEGO, CA — Two novel antisense oligonucleotide therapies in development significantly reduced levels of lipoprotein(a) in individuals with elevated Lp(a) in two clinical trials, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback